P31 – Gene Electrotransfer for Antibody Production

To address the challenges of conventional immune and antibody protein therapies, in vivo DNA-based delivery can turn the site of administration into a ‘factory’ that produces the drug of interest in a cost-efficient and therapeutically effective manner. This special session invites the different actors in the field of therapeutic gene electrotransfer to share their work, discuss progress and challenges, and together advance clinical translation.